{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:17:12Z","timestamp":1789067832329,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.03.040","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T12:56:54Z","timestamp":1561035414000},"page":"4787-4793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2974-6853","authenticated-orcid":false,"given":"Sachin","family":"Mani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9439-0828","authenticated-orcid":false,"given":"Franklin R.","family":"Toapanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdausi","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Mari","family":"Svennerholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Devriendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Phalipon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo B.","family":"Sztein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.03.040_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990\u20132016","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0010","first-page":"29","article-title":"The global problem of childhood diarrhoeal diseases: emerging strategies in prevention and management","volume":"5","author":"Mokomane","year":"2018","journal-title":"Ther Adv Infect Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2019.03.040_b0015","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1016\/j.vaccine.2016.02.076","article-title":"Status of vaccine research and development for enterotoxigenic Escherichia coli","volume":"34","author":"Bourgeois","year":"2016","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2019.03.040_b0020","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/j.vaccine.2016.02.075","article-title":"Status of vaccine research and development for Shigella","volume":"34","author":"Mani","year":"2016","journal-title":"Vaccine"},{"issue":"49 Pt A","key":"10.1016\/j.vaccine.2019.03.040_b0025","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1016\/j.vaccine.2017.05.034","article-title":"Human immune responses against Shigella and enterotoxigenic E. coli: current advances and the path forward","volume":"35","author":"McArthur","year":"2017","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2019.03.040_b0030","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.vaccine.2017.05.005","article-title":"Correlates of protection for enteric vaccines","volume":"35","author":"Holmgren","year":"2017","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2019.03.040_b0035","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1128\/IAI.00459-07","article-title":"Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh","volume":"75","author":"Qadri","year":"2007","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1128\/CVI.00526-15","article-title":"Enumeration of gut-homing \u03b27-positive, pathogen-specific antibody-secreting cells in whole blood from enterotoxigenic Escherichia coli- and vibrio cholerae-infected patients, determined using an enzyme-linked immunosorbent spot assay technique","volume":"23","author":"Bhuiyan","year":"2015","journal-title":"Clin Vacc Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0045","doi-asserted-by":"crossref","first-page":"e2822","DOI":"10.1371\/journal.pntd.0002822","article-title":"Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults","volume":"8","author":"Alam","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/erv.12.12","article-title":"Recent progress toward an enterotoxigenic Escherichia coli vaccine","volume":"11","author":"Svennerholm","year":"2012","journal-title":"Expert Rev Vacc"},{"issue":"2","key":"10.1016\/j.vaccine.2019.03.040_b0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/CDLI.8.2.424-428.2001","article-title":"Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine","volume":"8","author":"Jertborn","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1086\/314543","article-title":"Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group","volume":"179","author":"Savarino","year":"1999","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2019.03.040_b0065","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1128\/IAI.69.5.2853-2857.2001","article-title":"Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine","volume":"69","author":"Hall","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.03.040_b0070","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1016\/j.vaccine.2007.03.034","article-title":"Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico","volume":"25","author":"Sack","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0075","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/427662","article-title":"Serologic correlates of protection against enterotoxigenic Escherichia coli diarrhea","volume":"191","author":"Rao","year":"2005","journal-title":"J Infect Dis"},{"issue":"52","key":"10.1016\/j.vaccine.2019.03.040_b0080","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.vaccine.2019.03.040_b0085","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1016\/j.vaccine.2016.04.055","article-title":"Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine","volume":"34","author":"Lundgren","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.040_b0090","author":"Akhtar","year":"2018","journal-title":"Vaccine"},{"issue":"Oct","key":"10.1016\/j.vaccine.2019.03.040_b0095","first-page":"1","article-title":"Animal enterotoxigenic Escherichia coli","volume":"7","author":"Dubreuil","year":"2016","journal-title":"EcoSal Plus"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tim.2011.11.002","article-title":"The pig: a model for human infectious diseases","volume":"20","author":"Meurens","year":"2012","journal-title":"Trends Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.03.040_b0105","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/mi.2012.37","article-title":"Targeting aminopeptidase N, a newly identified receptor for F4ac fimbriae, enhances the intestinal mucosal immune response","volume":"5","author":"Melkebeek","year":"2012","journal-title":"Mucosal Immunol"},{"issue":"15","key":"10.1016\/j.vaccine.2019.03.040_b0110","doi-asserted-by":"crossref","first-page":"9713","DOI":"10.1074\/jbc.M807866200","article-title":"Recognition of blood group ABH type 1 determinants by the FedF adhesin of F18-fimbriated Escherichia coli","volume":"284","author":"Coddens","year":"2009","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.vaccine.2019.03.040_b0115","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.dci.2010.06.009","article-title":"Enterotoxigenic Escherichia coli (K88) induce proinflammatory responses in porcine intestinal epithelial cells","volume":"34","author":"Devriendt","year":"2010","journal-title":"Dev Comp Immunol"},{"issue":"46","key":"10.1016\/j.vaccine.2019.03.040_b0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13567-015-0264-2","article-title":"F4+ ETEC infection and oral immunization with F4 fimbriae elicits an IL-17-dominated immune response","volume":"21","author":"Luo","year":"2015","journal-title":"Vet Res"},{"issue":"2","key":"10.1016\/j.vaccine.2019.03.040_b0125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1128\/IAI.67.2.520-526.1999","article-title":"Receptor-dependent immune responses in pigs after oral immunization with F4 fimbriae","volume":"67","author":"Van den Broeck","year":"1999","journal-title":"Infect Immun"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2019.03.040_b0130","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1016\/S0264-410X(02)00220-7","article-title":"Different kinetic of antibody responses following infection of newly weaned pigs with an F4 enterotoxigenic Escherichia coli strain or an F18 verotoxigenic Escherichia coli strain","volume":"20","author":"Verdonck","year":"2002","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2019.03.040_b0135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13567-015-0210-3","article-title":"Maternal immunity enhances systemic recall immune responses upon oral immunization of piglets with F4 fimbriae","volume":"23","author":"Nguyen","year":"2015","journal-title":"Vet Res"},{"issue":"29","key":"10.1016\/j.vaccine.2019.03.040_b0140","doi-asserted-by":"crossref","first-page":"11809","DOI":"10.1073\/pnas.1301975110","article-title":"Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic Escherichia coli infection","volume":"110","author":"Virdi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.03.040_b0145","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations (*)","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0155","doi-asserted-by":"crossref","first-page":"e0005291","DOI":"10.1371\/journal.pntd.0005291","article-title":"Impact of CD4+ T cell responses on clinical outcome following oral administration of wild-type enterotoxigenic Escherichia coli in humans","volume":"11","author":"McArthur","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"5802","key":"10.1016\/j.vaccine.2019.03.040_b0160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1132742","article-title":"Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells","volume":"314","author":"Mora","year":"2006","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0165","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41598-018-20740-3","article-title":"Activated T follicular helper-like cells are released into blood after oral vaccination and correlate with vaccine specific mucosal B-cell memory","volume":"8","author":"Cardeno","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/infdis\/125.1.12","article-title":"Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection","volume":"125","author":"DuPont","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.040_b0175","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/infdis\/164.3.533","article-title":"Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei","volume":"164","author":"Formal","year":"1991","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.03.040_b0180","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/oxfordjournals.aje.a116134","article-title":"Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago","volume":"134","author":"Ferreccio","year":"1991","journal-title":"Chile Am J Epidemiol"},{"issue":"12","key":"10.1016\/j.vaccine.2019.03.040_b0185","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1017\/S0950268814000260","article-title":"Recent trends in the epidemiology of shigellosis in Israel","volume":"142","author":"Cohen","year":"2014","journal-title":"Epidemiol Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0190","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/jcm.32.4.1092-1094.1994","article-title":"Epidemic spread of Shigella sonnei shigellosis and evidence for development of immunity among children attending day-care centers in a communal settlement (Kibbutz)","volume":"32","author":"Lerman","year":"1994","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.03.040_b0195","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/jcm.29.2.386-389.1991","article-title":"Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis","volume":"29","author":"Cohen","year":"1991","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2019.03.040_b0200","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.03.040_b0205","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/infdis\/155.6.1260","article-title":"Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine","volume":"155","author":"Black","year":"1987","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.03.040_b0210","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/clinids\/15.2.346","article-title":"Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides","volume":"15","author":"Robbins","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2019.03.040_b0215","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/infdis\/161.5.821","article-title":"Polysaccharide-protein conjugates: a new generation of vaccines","volume":"161","author":"Robbins","year":"1990","journal-title":"J Infect Dis"},{"issue":"9046","key":"10.1016\/j.vaccine.2019.03.040_b0220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2019.03.040_b0225","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1128\/iai.64.10.4074-4077.1996","article-title":"Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers","volume":"64","author":"Cohen","year":"1996","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2019.03.040_b0230","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0235","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.4049\/jimmunol.0803141","article-title":"A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection","volume":"182","author":"Phalipon","year":"2009","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0240","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/acs.bioconjchem.5b00617","article-title":"A synthetic carbohydrate conjugate vaccine candidate against shigellosis: improved bioconjugation and impact of alum on immunogenicity","volume":"27","author":"van der Put","year":"2016","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.vaccine.2019.03.040_b0245","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1073\/pnas.96.9.5194","article-title":"Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1","volume":"96","author":"Pozsgay","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2019.03.040_b0250","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1084\/jem.20130914","article-title":"B lymphocytes undergo TLR2-dependent apoptosis upon Shigella infection","volume":"211","author":"Nothelfer","year":"2014","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2019.03.040_b0255","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrmicro3415","article-title":"Pathogen manipulation of B cells: the best defence is a good offence","volume":"13","author":"Nothelfer","year":"2015","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0260","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.4049\/jimmunol.0900978","article-title":"Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity","volume":"184","author":"Sellge","year":"2010","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mib.2010.08.014","article-title":"Shigella deploy multiple countermeasures against host innate immune responses","volume":"14","author":"Ashida","year":"2011","journal-title":"Curr Opin Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0270","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.coi.2011.06.001","article-title":"Shigella are versatile mucosal pathogens that circumvent the host innate immune system","volume":"23","author":"Ashida","year":"2011","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0275","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1128\/IAI.66.4.1342-1348.1998","article-title":"An essential role for gamma interferon in innate resistance to Shigella flexneri infection","volume":"66","author":"Way","year":"1998","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0280","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1128\/iai.63.1.289-296.1995","article-title":"Persistence of local cytokine production in shigellosis in acute and convalescent stages","volume":"63","author":"Raqib","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.03.040_b0285","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/gut.38.3.328","article-title":"Local entrapment of interferon [gamma] in the recovery from Shigella dysenteriae type 1 infection","volume":"38","author":"Raqib","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2019.03.040_b0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0264-410X(95)80017-8","article-title":"Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers","volume":"13","author":"Karnell","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.040_b0295","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1128\/iai.64.11.4542-4548.1996","article-title":"Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG","volume":"64","author":"Kotloff","year":"1996","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0300","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4049\/jimmunol.164.4.2221","article-title":"Production of IFN-\u03b3 and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a shiga toxin-deleted Shigella dysenteriae type 1 strain","volume":"164","author":"Samandari","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.03.040_b0305","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1128\/IAI.70.4.2016-2021.2002","article-title":"Phase 1 evaluation of a vriG deleted Shigella sonnei live, attenuated vaccine (strain WRSS1) in healthy adult volunteers","volume":"70","author":"Kotloff","year":"2002","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2019.03.040_b0310","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/hv.4746","article-title":"Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media","volume":"3","author":"Kotloff","year":"2007","journal-title":"Hum Vaccin"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12967-018-1439-1","article-title":"T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans","volume":"16","author":"Toapanta","year":"2018","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.vaccine.2019.03.040_b0320","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0325","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.040_b0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clim.2013.03.009","article-title":"Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a","volume":"148","author":"Wahid","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2019.03.040_b0335","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clim.2011.02.003","article-title":"Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates","volume":"139","author":"Simon","year":"2011","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.040_b0340","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.vaccine.2008.10.081","article-title":"Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates","volume":"27","author":"Simon","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.040_b0345","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vacc Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2019.03.040_b0350","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2019.03.040_b0355","unstructured":"Correlates of vaccine-induced protection: methods and implication. WHO\/IVB\/13.01 <http:\/\/www.who.int\/iris\/bitstream\/10665\/84288\/1\/WHO_IVB_13.01_eng.pdf> [accessed on 11.20.2018]."},{"issue":"8","key":"10.1016\/j.vaccine.2019.03.040_b0360","doi-asserted-by":"crossref","first-page":"e0004926","DOI":"10.1371\/journal.pntd.0004926","article-title":"A randomised, double blind, placebo-controlled challenge study to assess the protective efficacy of the single-dose oral typhoid vaccine, M01ZH09","volume":"10","author":"Darton","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2019.03.040_b0365","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12967-016-0819-7","article-title":"Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans","volume":"1","author":"Fresnay","year":"2016","journal-title":"J Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1930372X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1930372X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:17Z","timestamp":1759401197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1930372X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":73,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X1930372X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}